The strongest progression among the index values was recorded by the Galapagos. The biotechnology stock, which underperformed last year, climbed 3.54% to 27.46 euros. It was followed by Umicore, another loser in 2024. The metals group rebounded by 2.26% to 10.18 euros.
Among the stocks in the index, the losses were mainly suffered by Melexis. The designer of chips for the automotive sector lost 1.95% to a closing price of 55.40 euros.
Brokers’ opinions on Melexis, Bekaert, EVS and Fagron
After real estate companies and holding companies, KBC Securities recommends four other companies (all rated “buy”) whose growth prospects are not reflected in their valuation.
Pour Melexis (target 85 euros), the analyst believes that the market reacted too strongly to the announcement of the latest results. In the long term, management expects continued growth. “In the short term, the group has implemented a share buyback program for an amount of 50 million euros.”
Bekaert (objective 55 euros) is appreciated for the tendency to turn towards new markets with higher added value, which should make it possible to reduce the weight of sectors such as construction or automobiles. “Management took advantage of the attractive valuation to launch a significant share buyback program.”
ALL (objective 40.5 euros) is appreciated for its ability to expand beyond its traditional niche (broadcasting of sporting events) towards new segments of the audiovisual market. “The group is expected to reach the peak of its objectives in 2024, with the ambition to increase its turnover to more than €350 million by 2030.”
Fagron (target 24 euros) is still estimated to be significantly undervalued, with strong growth in its cash flows expected for the years to come. “The group operates in a market segment relatively untouched by the recession. »
On the general market
Don’t say gained 6.53% to a closing price of 146.80 euros. The stock was advised by analyst Paul D’Hoore.
Fixed climbs 5.43% to 29.10 euros. Real estate investor Vastned Belgium has completed the acquisition of its Dutch parent company Vastned. He also adopted his name.
Among the smallest values, Sequana Medical fell 19.93% to 2.45 euros.
